(Q35681816)

English

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

scientific article published on 10 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

5

object named as

Marc Ladanyi

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

3

object named as

William Pao

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

17

object named as

Mark G Kris

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Valerie W Rusch

2

object named as

Valerie Rusch

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

16

object named as

Ronglai Shen

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Maureen F Zakowski

14

object named as

Maureen Zakowski

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Robert T Heelan

15

object named as

Robert T Heelan

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

4

object named as

Jamie E Chaft

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Bhuvanesh Singh

13

object named as

Bhuvanesh Singh

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Christopher G Azzoli

8

object named as

Christopher G Azzoli

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

object named as

Naiyer A Rizvi

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

12

object named as

Bernard Park

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Vincent A Miller

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Lee M Krug

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Manjit Bains

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Robert Downey

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Raja Flores

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

10 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

3500-3506

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

12 July 2018

Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

25 September 2018

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

25 September 2018

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

25 September 2018

Practical management of patients with non-small-cell lung cancer treated with gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

25 September 2018

High-throughput oncogene mutation profiling in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261615

15 November 2018

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21558399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-10-2102

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

release_yohnzqn3sndbfb2yzwzzh2hucy

1 reference

https://api.fatcat.wiki/v0/release/yohnzqn3sndbfb2yzwzzh2hucy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35681816&oldid=2033409351"